Background
==========

Aging is associated with functional decline, loss of autonomy, and a wide spectrum of adverse outcomes as mooted in literature.[@b1-cia-11-1675] Due to a global rise in life expectancy, maintaining physical function and preventing disability in advanced age are among the major clinical and public health priorities.[@b2-cia-11-1675],[@b3-cia-11-1675] Frailty is one of the main factors that suppresses successful aging and leads to adverse health consequences, mainly falls and delirium after minor stressor.[@b4-cia-11-1675]

The concept of frailty can be seen as a multidimensional, transitional state of increased vulnerability and loss of the ability to adapt to stress.[@b5-cia-11-1675] It has also been recognized as a distinct clinical syndrome of cumulative decline in many physiological systems during lifetime[@b6-cia-11-1675],[@b7-cia-11-1675] with a biological basis.[@b8-cia-11-1675] Given this recognition, numerous physiological systems have been studied in the light of their relationship with frailty.[@b9-cia-11-1675] Among these physiological systems are inflammation, neuromuscular dysfunction, endocrine dysregulation, immune dysfunction, abnormalities in energy metabolism,[@b9-cia-11-1675] and central nervous system failure.[@b10-cia-11-1675]

L-carnitine (β-hydroxy-γ-N-trimethylamino-butyric acid) is an essential dietary nutrient, which can be synthesized endogenously.[@b11-cia-11-1675] L-carnitine is a metabolically important compound,[@b11-cia-11-1675],[@b12-cia-11-1675] which has several functions in the human body.[@b8-cia-11-1675] The main function of L-carnitine in cellular energy metabolism is as a requisite in the transport of the long chain fatty acids to the inner mitochondrial membrane and the site of beta oxidation.[@b11-cia-11-1675] The other functions of L-carnitine include buffering of mitochondrial acyl CoA/CoA ratio, oxidation of branched amino acids, and having protective effects on the endogenous antioxidant defense system.[@b13-cia-11-1675]

Clinically, L-carnitine is important for fatty acid metabolism, as a antiradical agent, and for prevention against oxidative damage.[@b11-cia-11-1675] L-carnitine supplementation has been studied in a few diseases and in adults with L-carnitine deficiency, such as in cancer, HIV, and kidney failure patients in intervention studies. The supplementation showed a significant favorable effect on cancer-related anorexia,[@b14-cia-11-1675] cachexia,[@b15-cia-11-1675] and fatigue.[@b15-cia-11-1675]--[@b17-cia-11-1675] It is also known to have an enhancing metabolic and immunological effect on HIV patients[@b18-cia-11-1675],[@b19-cia-11-1675] and increased muscle strength in kidney failure patients.[@b20-cia-11-1675]

Among older adults, L-carnitine supplementation was beneficial in improving physical, mental, and cognitive function.[@b21-cia-11-1675] Improvement in body composition and fatigue has also been reported with L-carnitine supplementation.[@b22-cia-11-1675] Positive effects on mood and cognitive functions were demonstrated following a 7-week supplementation of L-carnitine among older adults with depression.[@b23-cia-11-1675]

Aging-related changes in biological system, particularly the mitochondria dysfunction, suggest that L-carnitine deficiency may be associated with aging and age-related disorders. A relationship between L-carnitine status and frailty was reported in a study by Crenstil,[@b9-cia-11-1675] with L-carnitine deficiency deduced to related pathophysiological changes in frailty, such as neuromuscular abnormalities, inflammation, decrease of energy production, and immune impairment.[@b7-cia-11-1675] However, more information regarding the relationship between L-carnitine and frailty is required. The same urge is needed to conduct intervention and experimental studies using L-carnitine supplementation among frail elderly people. Up to date, the published studies that have investigated the effectiveness of L-carnitine on frailty are sparse. Therefore, the aim of the present study was to determine the effectiveness of L-carnitine supplementation on frailty status among Malaysian older adults with prefrailty.

Methodology
===========

This study is a double-blind, randomized, placebo-controlled clinical trial with L-carnitine supplementation among pre-frail older adults. The primary outcomes of the intervention were frailty status, frailty biomarkers, and physical function, while the secondary outcomes included nutritional status, body composition, and cognitive function. The study protocol was approved by the Department of Social and Welfare (December 13, 2013) and Universiti Kebangsaan Malaysia Medical Research and Ethics Committee (UKM 1.5.3.5/244/NN-149-2013). All patients provided written informed consent. The intervention was carried out from March 23 to July 14, 2014. The recruited subjects were assessed three times through the intervention period at baseline, week 5, and week 10. [Figure 1](#f1-cia-11-1675){ref-type="fig"} summarizes the subjects' recruitment in a flowchart. The sample size was calculated using Chan formula for sample size calculation in randomized controlled clinical trials.[@b24-cia-11-1675] The mean and standard deviations were taken from a similar randomized clinical trial Rondanelli et al[@b25-cia-11-1675] conducted to determine the improvement of the hand grip as a primary outcome among elderly individuals using amino acid supplementation. It showed significant changes in the mean of the hand grip among the intervention group. Ninety percent power and 0.05 level of confidence were assumed to calculate the sample size. The final sample size calculation deemed required was 25 subjects in each group.

Subjects' selection
-------------------

This study is a part of a larger nationwide longitudinal study on neuroprotective model for healthy longevity among Malaysian older adults as reported earlier.[@b26-cia-11-1675] This present study was conducted at the state of Selangor in Malaysia. Subjects were selected through a multistage random sampling in order to assure the representativeness of the three major community ethnic groups in Malaysia (Malay, Chinese, and Indian) from ten different districts. The chosen districts were with elderly population making up at least 10% of the total population according to Malaysian Department of Statistics. More than 600 community dwelling individuals aged 60 years and above, with no known terminal and mental illnesses, were invited to participate in a health screening. Out of the 473 subjects consented and participated in the screening, 159 subjects were categorized as prefrail according to Fried criteria.[@b27-cia-11-1675] These participants were then shortlisted according to the study criteria. Subjects who had any of the following were excluded: uncontrolled diabetes mellitus (glycated haemoglobin \[HbA~1c~\] \>7.5%), cognitive impairment (Mini-Mental State Examination \[MMSE\] \<18), being malnourished with muscle wasting, and taking L-carnitine supplements for the past year prior to the study. A total of 58 subjects who consented to join the study were randomized into two groups using block randomization stratified by sex. Code numbers were given to the subjects and written on folded papers for randomized selection. Randomized selection of the numbers were done by one of the research team members who was totally uninvolved in this study.

Preparation of the supplements
------------------------------

L-carnitine supplement (500 mg/cap) was purchased from Cambert (M) Sdn Bhd, (Selangor, Malaysia). They had been repacked a day before the intervention in dark white colored pharmaceutical bottles to assure blinding. The placebo capsules (corn starch filling) were made at the pharmaceutical laboratory, Faculty of Pharmacy, UKM, Kuala Lumpur campus, by a trained pharmacist using a capsule filling machine, Product type: JCT. The placebo capsules were prepared 3 weeks before the intervention, and packed in the same bottles that the L-carnitine supplements were repacked in. The placebo capsules were completely identical when compared with the L-carnitine supplement in terms of color, size, and appearance. However, the only difference was in the weight; the placebo capsules weight range was from 520 to 550 mg, while the L-carnitine capsules weight ranged from 600 to 610 mg. It was difficult to recognize the difference in the weight by visual observation.

Intervention and ensuring compliance
------------------------------------

Detailed briefing about the study and the benefits of the intervention was given to the subjects at the baseline assessment. All subjects were informed that they had to take the supplementation as prescribed on the bottles (one capsule \[500 mg\], tid, for 10 weeks), and their participation was optional. Each subject was given a booklet, including a timetable of consuming the supplement. Participants were requested to fill in daily the number and time of the capsules they took. On the follow-up assessments, the supplementation bottles were collected from the subjects in each group, and the remaining capsules were calculated and reported on the data collection sheet. The subjects were also asked to report the general expected side effects due to any intervention, both positive and negative records, after the intervention period at week 10.

Data collection
---------------

Data collection was carried out at preassigned community halls known to all subjects. All subjects were informed on phone to fast on the assessment day. The baseline assessment included a detailed sociodemographic data, medical history, frailty status assessment, physical function, cognitive function, nutritional status, and selected frailty biomarkers. The second assessment occurred at week 5, which included frailty status assessment, physical function, cognitive function, and nutritional status. The last assessment occurred at week 10 and included the same assessments as per baseline. All the assessments were carried out by trained postgraduates team in health sciences (from three different disciplines: nutrition, physiotherapy, and biomedical sciences) who were completely blinded about the intervention groups.

Study instruments and tools
---------------------------

### Frailty assessment

Fried criteria, a well-known frailty assessment tool that is widely used in clinical research,[@b28-cia-11-1675] were utilized in this study. The criteria included assessment of shrinking, exhaustion, weakness, slowness, and low physical activity. Till date, there are no Malaysian cutoff points for hand grip and walking speed, and so the original cutoff points from Fried et al were used.[@b27-cia-11-1675] The second tool was the Frailty Index (FI) accumulation of deficit (40 items), which is the short form of the original 70-item FI accumulation of deficits. This tool is reported to be reliable for frailty assessment in clinical research.[@b28-cia-11-1675] It is recommended to be used in intervention studies for frailty prevention and treatment.[@b29-cia-11-1675] In the present study, FI assessment was done following the standard procedures described and standardized in a study by Searle et al.[@b30-cia-11-1675] The convergent validity of the two frailty assessment instruments was tested by correlating the measures with each other and other health status measures.[@b28-cia-11-1675] Significant correlations were found and the two instruments were recommended to be used in frailty assessment in clinical research. Physical activity was assessed using Physical Activity Scale for Elderly (PASE).[@b31-cia-11-1675] In a recent study, PASE was also validated in Asian population, with acceptable test--retest reliability (intraclass correlation coefficient =0.81).[@b32-cia-11-1675]

### Nutritional status assessment

Nutritional status assessment included anthropometric measurements (weight, height, mid-upper arm circumferences, waist circumferences, hip circumferences, and calf circumferences) and was conducted by trained postgraduates in health sciences according to standard techniques.[@b33-cia-11-1675] Height measurement was done using a height measuring device (Seca 214), to the nearest 0.1 m. Body weight was measured using a digital scale (Tanita HD-319 scale, Sin Huat Hin Machinery (M) Sdn.Bhd., Serdang, Kuala Lumpur, Malaysia), to the nearest 0.1 kg. Circumferences measurements were done using a flexible, nonextensible measuring tape. Body composition was done using bio electric impedance (BIA) (Korean brand, model Inbody S10^®^, Inbody Malaysia, Kuala Lumpur, Malaysia). Fat mass, fat percentage, fat free mass, soft lean mass, skeletal muscle mass, and basal metabolic rate were extracted from the machine output. Cognitive function was assessed through the MMSE,[@b34-cia-11-1675] using the validated Malaysian version.[@b35-cia-11-1675] Physical function assessment included hand grip test, 30-second chair stand test, 8-ft time up and go test, 2-minute step test, gait speed test at rapid pace, peak expiratory flow rate (PEFR) test, and shoulder strength test. The subjects were given demonstration on each test before they performed the tests. The hand grip test was done using a digital hand dynamometer (Jamar Plus, Model: 563213, USA), among the community dwelling elderly; the reliability of grip strength using the dynamometer was 0.954 using test and retest reliability.[@b36-cia-11-1675] Shoulder strength test was done using customized set, consisting of digital gauge and adjustable Velcro loop with interlock straps to adjust it according to the subject's height. The reliability test of the shoulder strength was done using test and retest method and the correlation coefficient ranged from 0.96 to 0.98.[@b37-cia-11-1675] The 30-second chair stand test was performed to assess the lower limbs strength; this test was reported to be a valid and reliable test for measuring lower body strength among the community dwelling elderly.[@b38-cia-11-1675] The 8-ft time up and go test was used to assess mobility and balance. This test is one of the basic functional and mobility tests for the elderly with a documented validity and reliability study.[@b39-cia-11-1675] With respect to gait speed test, different distances all have excellent reliability range from 0.96 to 0.99; also, 6 m gait speed was validated by concurrent validity of 4 and 10 m walling test.[@b40-cia-11-1675] The 2-minute step test was included in the test battery as an aerobic endurance assessment. The PEFR test was done for respiratory function assessment; it was done using peak flow meter (Mini-Wright, USA) with a disposable mouth piece. All of the fore mentioned physical function tests were done following the standard procedures in senior fitness test. Subjects were asked to perform the tests twice with 5 minutes rest between the two trials. The activity of daily living was assessed using Katz Index of Independent in Activities of Daily Living scale.[@b41-cia-11-1675] The instrumental activity of daily living was assessed using Lawton Instrumental Activities of Daily Living scale (IADL).

A total amount of 20 mL fasting venous blood was drawn at baseline and week 10 to assess the biochemical parameters. The blood samples were immediately transferred from the place of data collection to the Pathology and Clinical Laboratory (M) Sdn Bhd. The samples were centrifuged using TOMY Flexin Bench Top centrifuge at 350 rpm/5 minutes, aliquoted in micro centrifuge tubes, and then stored at −80°C. The biochemical analysis for the routine tests, including fasting blood sugar, HBA~1c~, lipid profile, kidney function, and liver function, was done at the lab.

Frailty biomarkers, including interleukin (IL)-6, tumor necrosis factor (TNF)-α, and insulin-like growth factor (IGF)-1, in addition to plasma free L-carnitine and total L-carnitine were analyzed at the Bioserasi Laboratory of Universiti Kebangsaan Malaysia. The serum level of L-carnitine and total L-carnitine was done following a Prieto et al method.[@b42-cia-11-1675] Detection of IL-6, TNF-α, IGF-1, and vitamin D in the serum was done using enzyme-linked immunosorbent assay kits (R&D Systems, Inc., Minneapolis, MN, USA) and assessed using spectrophotometry.

Statistical analysis
--------------------

All statistical analyses were carried out using the Statistical Package for Social Sciences software, version 21.0 (IBM Corporation, Armonk, NY, USA). An alpha level of 0.05 was considered for all the statistical tests used in the study. Normality test was checked for all of the continuous variables and the data were not normally distributed. Mann--Whitney test was employed for the continuous variables and chi-square for the categorical variables to determine the characteristics differences between the two groups (ie, L-carnitine and placebo). The effects of the intervention on the outcome variables for each group were assessed using the nonparametric tests (Friedman test and Wilcoxon test). Also, the percentage of mean change was calculated for each subject from baseline to week 5 and from baseline to week 10, and then Mann--Whitney test was employed to determine the difference in the mean of the percentage of mean difference between the two groups.

Results
=======

Subjects characteristics
------------------------

A total of 50 subjects out of 58 were recruited and completed the study, with a response rate of 89.7%. Only six subjects dropped out and two subjects were excluded from the final analysis due to acute disease on the day of the data collections. Both groups had an almost similar age mean(68.2±6.3 years for the intervention group and 68.8±6.5 years for the placebo group). There were no significant differences between the two groups in terms of sex, ethnicity, marital status, living arrangement, level of education, and employment status and also medical history (with an exception of vision problem), as shown in [Table 1](#t1-cia-11-1675){ref-type="table"}. There were also no significant differences between groups on frailty status score, physical function, nutritional status, and the biochemical tests using Mann--Whitney test.

Friedman test was employed to determine the changes in the mean of the outcome variables at baseline, week 5, and week 10. Results showed that there was a significant improvement in the mean FI score and hand grip test in the L-carnitine group (*P*\<0.05 for both parameters) while there were no significant changes in the mean scores in the placebo group. The changes in the mean of the functional tests (activity of daily living \[ADL\], instrumental activity of daily living \[IADl\], and physical function) were not significant in both L-carnitine and placebo group, except for shoulder strength test and physical activity (PASE) of which both groups showed significant improvements (*P*\<0.05 for all parameters). The nonparametric Wilcoxon test was employed to determine the changes in the frailty biomarkers and L-carnitine derivatives before and after the intervention. The results showed no significant differences in the blood level of these biomarkers after the intervention. A favorable effect was noticed on the level of IL-6 and IGF-1, but this effect did not reach a significant level. The changes in the free L-carnitine, total L-carnitine, and acyl L-carnitine were not significant in both groups, as shown in [Table 2](#t2-cia-11-1675){ref-type="table"}. There were no significant changes in the secondary outcome variables: nutritional status, body composition, and cognitive using Friedman test. Similarly, there were no significant changes in fasting blood sugar, HBA~1c~, lipid profile, liver function, and kidney function using Wilcoxon test, for all of the tests.

Further analysis was done by calculating the percentage of mean changes from the outcome variables at 5 and 10 weeks. A significant favorable effect of L-carnitine was recorded in frailty score and hand grip (*P*\<0.01, *P*\<0.05), respectively, as shown in [Figure 2](#f2-cia-11-1675){ref-type="fig"}. The percent change in FI score from baseline to 10 weeks was −34.4% in L-carnitine group compared to −2.1% in placebo group (*P*\<0.001) ([Figure 2A](#f2-cia-11-1675){ref-type="fig"}). The corresponding figures for handgrip strength was 7.2% for the L-carnitine group as compared to −3.6% in the placebo group (*P*\<0.05) ([Figure 2B](#f2-cia-11-1675){ref-type="fig"}). There were favorable effects and improvements in some of other physical function tests, but these improvements were not significant between the groups, such as the improvement in PEFR test ([Figure 2C](#f2-cia-11-1675){ref-type="fig"}).

[Figure 3](#f3-cia-11-1675){ref-type="fig"} shows the percent change in all of the biomarkers tests from baseline to 10 weeks. Significant differences between the groups were not found for all of the tested biomarkers. However, it is clearly noticeable that the decrease in percent change for IL-6 level was better in the L-carnitine group compared to placebo group. A favorable increase in the IGF-1 level in the L-carnitine group was also observed compared to placebo group. The rest of the outcome variables, nutritional status, body composition, biochemical data, and cognitive function, did not show any significant differences between the L-carnitine and placebo groups in the percent of mean changes in the intervention period.

The transition in the frailty status after the intervention
-----------------------------------------------------------

[Figure 4A](#f4-cia-11-1675){ref-type="fig"} shows the changes in the frailty scores for the L-carnitine group. Three subjects (11.5%) changed from prefail to normal. The percentage of subjects with one deficit increased from 18 subjects (69.2%) to 19 subjects (73.1%) after 10 weeks, while the percentage of subjects with two deficits decreased from ten subjects (30.8%) to four subjects (15.4%) after 10 weeks' intervention. [Figure 4B](#f4-cia-11-1675){ref-type="fig"} shows the changes in frailty scores in the placebo group. The improvement in the frailty status was less compared to L-carnitine group. Only one subject (4.2%) improved to normal status. No changes in the percentage of subjects with one deficit were observed, while the percentage decreased from six subjects (25%) to five subjects (20.8%) for those with two deficits. [Figure 5](#f5-cia-11-1675){ref-type="fig"} shows that four subjects (15.1%) with weakness were improved in L-carnitine group, while no improvement was found in the placebo group. For the exhaustion criteria, four subjects (15.4%) with exhaustion in the L-carnitine group changed to normal, while only one subject (4.2%) in the placebo group changed to normal in exhaustion criteria. For the low physical activity criteria, there were no changes in the L-carnitine group, while in the placebo group one subject (4.1%) changed from being mild to a moderately active status in terms of physical activity.

With respect to side effect recorded following the supplementation, it was found that there was a significantly higher percentage of subjects in the L-carnitine group. They reported feeling more energetic after the intervention (42.3%) as compared to the placebo group (16.7%) (*P*\<0.05). No significant adverse effects were reported in both the placebo and intervention groups ([Table 3](#t3-cia-11-1675){ref-type="table"}).

Discussion
==========

In the present study, both male and female subjects from three races composing of the Malaysian community were included. This made the sample representative of the study population (prefrail community dwelling Malaysian older adults). The dropout rate was 10.3%. Only six subjects dropped out, and two subjects were excluded from the final analysis. The intervention of the L-carnitine supplementation was well tolerated with good compliance; no adverse events or symptoms were reported from the subjects in both groups (placebo and L-carnitine).

To the best of our knowledge, this study is the first study of its kind that was conducted to investigate the effects of the L-carnitine supplement on frailty status either among the frail or prefrail elderly. Significant improvement in the L-carnitine group was only reported in the FI score and hand grip test. Moreover, the percentage of mean changes scores were significantly different between the two groups in frailty status and hand grip test. There were also no significant changes in the slowness criteria measure using gait speed between the L-carnitine and placebo groups. This might have happened due to the very small number (three) of the subjects who were found to be slow during baseline. Thus, the effects of L-carnitine in improving gait speed were not found. In this study, it appears that L-carnitine has a significant effect in improving frailty status in general, and hand grip test and exhaustion in particular. This improvement can be explained by the possible effect of L-carnitine in enhancing the mitochondrial function. This effect on mitochondria function includes correcting the cellular energy supply deficit, through facilitating the transport of long chain fatty acid -- the main source of energy in skeletal muscle -- into the mitochondria; facilitating the removal of short and medium chain fatty acid that accumulate during metabolism; and maintaining the proteins and lipids in the optimum level.[@b43-cia-11-1675] L-carnitine supplementation may increase the rate of fatty acid oxidation, preserve muscle glycogen, and increase the production of the adenosine triphosphate (ATP).[@b21-cia-11-1675] These suggested mechanisms improve the energetic metabolism in muscular skeletal tissue, and may have improved muscle function and reduced fatigue and exhaustion.

The findings of this study regarding the effect of L-carnitine on frailty were compared with other studies that reported the effects of L-carnitine supplementation among older adults. However, it should be noted that the findings were different and varied depending on the subjects' inclusion criteria and the targeted outcomes. In the present study, the effect of L-carnitine on frailty status was assessed using the FI accumulation of deficit tool. The results showed that FI scores significantly improved. Previous studies did not use the FI tool to define frailty status changes with L-carnitine supplementation; therefore, the effect of L-carnitine on frailty was further discussed according to its effects on Fried criteria (2001) and other physical and functional status tests. The effect of the intervention on hand grip test was significant, evidenced by significant differences in the percent of mean changes between the two intervention arms. It is well known that skeletal muscle is L-carnitine-dependent, as this muscle depends on fatty acid oxidation as the main source of energy.[@b44-cia-11-1675]

Exhaustion criteria improved due to the L-carnitine intervention evidenced by the significant association found between the L-carnitine group and self-report feelings of being more energetic. This finding is in line with other previous studies conducted on different groups of older adults and reported significant improvement in the physical and mental fatigue with the L-carnitine supplementation in different intervention periods, different intervention doses, and different L-carnitine derivatives.[@b21-cia-11-1675],[@b22-cia-11-1675],[@b45-cia-11-1675]

With respect to the criteria of low physical activity, the intervention with either L-carnitine or placebo showed significant changes in the PASE score using Friedman tests, but the percent of mean changes did not show significant difference between the two groups using Mann--Whitney test. Literature regarding intervention studies to determine the effects of L-carnitine on the physical activity among older adults or other subject groups is limited.

The effects of L-carnitine on functional status (ADL and IADL) and physical function were examined. Changes in the subjects' functional status (ADL and IADL) were not observed, implying that the effects on ADL and IADL were not significant. This could be attributed to the fact that that all subjects in both intervention arms were completely independent at baseline, as indicated by the full scores of ADL and very high scores of IADL.

The effects of L-carnitine on physical function was assessed by determining these effects on the eight physical function tests, including hand grip test, walking speed test, 2-minute step test, time up and go test, chair stand test, rapid pace test, shoulder strength test, and PEFR test. Despite the nonsignificant effects found from all these tests, the trend of the improvement was reported for the 2-minute step test, time up and go test, shoulder strength test, and PEFR test. In other words, the mean changes in these tests were toward the improvement in L-carnitine group compared to placebo. This might be due to the intervention period and dosage of L-carnitine.

The results of this study revealed no significant changes in the frailty biomarkers: IL-6, TNF-α, and IGF-1. However, the effects on IL-6 and IGF-1 were favorable. The majority of nutrition intervention studies targeted frailty as a major outcome; they assessed the effectiveness of the frailty using physical function, body composition and physical and cognitive function, with less focus on frailty biomarkers. However, few studies targeted the frailty biomarkers were found. L-carnitine theoretically had the ability to modulate the inflammatory status.[@b9-cia-11-1675],[@b46-cia-11-1675]

In clinical studies, L-carnitine showed a significant effect on modulating the inflammatory mediators C-reactive proteins[@b47-cia-11-1675],[@b48-cia-11-1675] and IL- 6 in hemodialysis patients.[@b49-cia-11-1675] A high dose of L-carnitine (6 g/day) has a significant reduction effect on the TNF-α level in HIV subjects.[@b18-cia-11-1675] From these reviewed studies, it can be concluded that L-carnitine modulates the hyperinflammation. Even in this documented effect, the mechanisms of how L-carnitine regulates this inflammation are not well understood. It was suggested that the reduction of the C-reactive protein and TNF-α levels is due to the effect of L-carnitine on reducing the level of IL-6, but the mechanism of how L-carnitine reduces IL-6 is still unknown.[@b49-cia-11-1675] But this study did not find this effect, which may be due to the fact that the subjects were prefrail and the inflammatory mediator level was not high, such as in the hemodialysis and HIV patients, and it may be due to the doses and intervention periods.

The results of the study revealed that the changes in free L-carnitine, total L-carnitines, and acyl L-carnitine blood level were not significant between the two groups. This means that the intervention with L-carnitine had no effect on the blood level of free, total, and acyl L-carnitine. Previous intervention studies of L-carnitine among the elderly were reviewed. The intervention with 2 g/day of L-carnitine for 6 months among centenarians showed no significant changes on free and total L-carnitine blood levels.[@b50-cia-11-1675] The consistent findings may be due to the fact that L-carnitine is a nonessential amino acid, which the body can synthesize from other amino acids in presence of other micronutrients.[@b50-cia-11-1675] Other reasons are the differences of the rate of L-carnitine uptake from different tissues, and the variation of storage of L-carnitine among different tissues (hepatic, renal, cardiac, skeletal muscle, and brain).[@b21-cia-11-1675] Cavallini et al[@b45-cia-11-1675] and Malaguarnera et al[@b21-cia-11-1675] conducted intervention studies among the elderly, but they did not report the L-carnitine blood level in their published data.

The current study did not find any significant effect on cognitive function among the study subjects. However, a previous study that included 66 centenarian adults who received L-carnitine supplementation showed significant improvement in MMSE due to the intervention.[@b21-cia-11-1675] Subjects' characteristics in the two studies might play a role in these differences. For instance, the participants' mean score of MMSE was very low (16.5) and the subjects had cognitive impairment,[@b21-cia-11-1675] whereas in this study, the mean score of MMSE, which was very high (27), indicated a normal cognitive function. So, it is not enough to conclude that L-carnitine has no effect on cognitive function based on the findings of the current study. Further research needs to be conducted on mild cognitive impairment subjects to support the findings reported in the literature.

Conclusion
==========

In conclusion, L-carnitine supplementation has the potential to improve physical function and reverse frailty, particularly for those suffering from fatigue and weakness with a convenient dose. Further research is needed to determine the efficacy of the L-carnitine supplementation among older adults with different frailty status, that is, frail, for a longer intervention period, different doses, and also combined with exercise.

This study utilized a randomized, placebo-controlled, double-blind, multicenter study design, a full 10-week supplementation, blood monitoring at baseline and posttreatment, and multiple assessments of various functions. However, this study is not without its limitations. It assessed the efficacy of the L-carnitine supplementation in short-term (10 weeks) and did not assess the efficacy for a longer period. Fatigue assessment was done using subjective methods. The nonstatistical significances in this study were assigned due to the low dose of L-carnitine given and the subjects' frailty status. The study did not measure the L-carnitine excretion from urine before and after the intervention, which might provide further explanation of L-carnitine distribution inside the human body. In the screening phase, the main limitations occurred in the frailty assessment tools. For Fried criteria, the study used the cutoff points of hand grip and gait speed from the original study published by Fried et al[@b27-cia-11-1675] conducted on a Western population rather than Asian.
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![Percent change in Frailty Index score and physical function.\
**Notes:** (**A**) Frailty Index, (**B**) Hand grip, (**C**) PEFR ^\*^*P*\<0.05, ^\*\*^*P*\<0.01, using independent *t*-test/Mann--Whitney test.\
**Abbreviation:** PEFR, peak expiratory flow rate.](cia-11-1675Fig2){#f2-cia-11-1675}

![Percent of mean change in frailty in selected biomarkers.\
**Notes:** (**A**) IL-6, (**B**) TNF-α, (**C**) IGF-1, no significant differences were found using independent *t*-test/Mann--Whitney test.\
**Abbreviations:** IL-6, interleukin 6; IGF-1, insulin-like growth factor-1; TNF-α, tumor necrosis factor-alpha.](cia-11-1675Fig3){#f3-cia-11-1675}

![Changes in the frailty scores according to Fried criteria.\
**Notes:** (**A**) L-carnitine group, (**B**) Placebo group.](cia-11-1675Fig4){#f4-cia-11-1675}

![Changes in the frailty deficit percentage before and after the intervention.\
**Notes:** (**A**) L-carnitine group, (**B**) placebo group.](cia-11-1675Fig5){#f5-cia-11-1675}

###### 

Sociodemographic characteristics of the L-carnitine and placebo groups

  Parameter                        L-carnitine group (n=26)   Placebo group (n=24)   *P*-value
  -------------------------------- -------------------------- ---------------------- --------------------------------------------------
  Mean age (years)                 68.2±6.3                   68.8±6.5               0.742[a](#tfn1-cia-11-1675){ref-type="table-fn"}
  Sex                                                                                
   Male                            14 (53.8%)                 9 (37.5%)              0.191[b](#tfn2-cia-11-1675){ref-type="table-fn"}
   Female                          12 (46.2%)                 15 (62.5%)             
  Race                                                                               
   Malay                           20 (76.9%)                 19 (79.2%)             0.656[b](#tfn2-cia-11-1675){ref-type="table-fn"}
   Chinese                         2 (7.7%)                   2 (8.3%)               
   Indian                          4 (15.4%)                  3 (8.3%)               
  Marital status                                                                     
   Married                         21 (80.8%)                 17 (70.8%)             0.313[b](#tfn2-cia-11-1675){ref-type="table-fn"}
   Not married                     5 (19.2%)                  7 (29.2%)              
  Living status                                                                      
   Living alone                    2 (7.7%)                   1(4.2%)                0.534[b](#tfn2-cia-11-1675){ref-type="table-fn"}
   Living with company             24 (92.3%)                 23 (95.8%)             
  Level of education                                                                 
   Mean schooling period (years)   10±3                       10±3                   1[a](#tfn1-cia-11-1675){ref-type="table-fn"}
  Employment status                                                                  
   Working                         3 (12%)                    1 (4.2%)               0.324[b](#tfn2-cia-11-1675){ref-type="table-fn"}
   Not working                     22 (88%)                   23 (95.8%)             

**Notes:**

Mann--Whitney test,

chi-square test.

###### 

Effects of the intervention on the primary outcome variables for the L-carnitine and placebo groups (presented as mean ± SD)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameters                              L-carnitine group\   *P*-value                                          Placebo group\   *P*-value
                                          (mean ± SD)                                                             (mean ± SD)      
  --------------------------------------- -------------------- -------------------------------------------------- ---------------- -------------------------------------------------------------------------------------------------
  Frailty lndex score                                                                                                              

   Baseline                               0.112±0.065          0.001[a](#tfn5-cia-11-1675){ref-type="table-fn"}   0.118±0.045      0.764[a](#tfn5-cia-11-1675){ref-type="table-fn"}

   5 weeks                                0.097±0.063                                                             0.116±0.056      

   10 weeks                               0.076±0.0578                                                            0.111±0.062      

  Hand grip (kg)                                                                                                                   

   Baseline                               23.6±6.9             0.012[a](#tfn5-cia-11-1675){ref-type="table-fn"}   22.8±6.5         0.058[a](#tfn5-cia-11-1675){ref-type="table-fn"}

   5 weeks                                23.6±7.3                                                                21.2±6.7         

   10 weeks                               24.4±7.4                                                                21.7±5.4         

  2-minute step test (step)                                                                                                        

   Baseline                               69±22                0.350[a](#tfn5-cia-11-1675){ref-type="table-fn"}   93±31            0.828[a](#tfn5-cia-11-1675){ref-type="table-fn"}

   5 weeks                                72±27                                                                   83±32            

   10 weeks                               76±23                                                                   85±23            

  Time up and go (s)                                                                                                               

   Baseline                               12.2±8.5             0.231[a](#tfn5-cia-11-1675){ref-type="table-fn"}   9.5±2.6          0.097[a](#tfn5-cia-11-1675){ref-type="table-fn"}

   5 weeks                                9.2±2.9                                                                 8.9±3.1          

   10 weeks                               9.4±1.9                                                                 9.5±2.9          

  Usual pace (s)                                                                                                                   

   Baseline                               6.5±1.2              0.234[a](#tfn5-cia-11-1675){ref-type="table-fn"}   6.6±1.6          0.106[a](#tfn5-cia-11-1675){ref-type="table-fn"}

   5 weeks                                6.2±1.5                                                                 6.5±1.4          

   10 weeks                               6.4±1.0                                                                 6.9±1.6          

  Rapid pace (s)                                                                                                                   

   Baseline                               4.9±0.7              0.509[a](#tfn5-cia-11-1675){ref-type="table-fn"}   5.1±1.3          0.397[a](#tfn5-cia-11-1675){ref-type="table-fn"}

   5 weeks                                5.1±1.3                                                                 5.0±1.5          

   10 weeks                               4.9±0.9                                                                 5.2±1.3          

  Shoulder strength (kg)                                                                                                           

   Baseline                               11.7±5.7             0.022[a](#tfn5-cia-11-1675){ref-type="table-fn"}   11.3±5.2         0.009[\*\*](#tfn4-cia-11-1675){ref-type="table-fn"},[a](#tfn5-cia-11-1675){ref-type="table-fn"}

   5 weeks                                11.9±5.6                                                                11.4±4.9         

   10 weeks                               13.8±5.9                                                                13.5±4.7         

  Peak expiratory flow rate (L/min)                                                                                                

   Baseline                               400±100              0.241[a](#tfn5-cia-11-1675){ref-type="table-fn"}   380±100          0.675[a](#tfn5-cia-11-1675){ref-type="table-fn"}

   5 weeks                                415±90                                                                  390±80           

   10 weeks                               410±80                                                                  380±90           

  Chair stand test (times/30 s)                                                                                                    

   Baseline                               11.0±3.3             0.07[a](#tfn5-cia-11-1675){ref-type="table-fn"}    11.3±3.6         0.05[a](#tfn5-cia-11-1675){ref-type="table-fn"}

   5 weeks                                11.5±3.8                                                                12.1±3.69        

   10 weeks                               11.3±3.8                                                                11.1±4           

  Physical activity scale PASE                                                                                                     

   Baseline                               155±60               0.025[a](#tfn5-cia-11-1675){ref-type="table-fn"}   150±70           0.013[\*](#tfn3-cia-11-1675){ref-type="table-fn"},[a](#tfn5-cia-11-1675){ref-type="table-fn"}

   5 weeks                                120±40                                                                  110±40           

   10 weeks                               150±50                                                                  130±30           

  Activity of daily living                                                                                                         

   Baseline                               6±0                  NA                                                 6±0              NA

   5 weeks                                6±0                                                                     6±0              

   10 weeks                               6±0                                                                     6±0              

  Instrumental activity of daily living                                                                                            

   Baseline                               13.9±0.4             0.765[a](#tfn5-cia-11-1675){ref-type="table-fn"}   13.6±0.9         NA

   5 weeks                                13.9±0.4                                                                13.6±0.9         

   10 weeks                               13.9±0.5                                                                13.6±0.9         

  **Frailty biomarkers**                                                                                                           

  Interleukin-6 (pg/mL)                                                                                                            

   Baseline                               6.1±2.9              0.699[b](#tfn6-cia-11-1675){ref-type="table-fn"}   6.2±2.3          0.05[b](#tfn6-cia-11-1675){ref-type="table-fn"}

   10 weeks                               5.9±7.3                                                                 8.9±8.2          

  Tumor necrosis factor-α (pg/mL)                                                                                                  

   Baseline                               5.9±2.0              0.802[b](#tfn6-cia-11-1675){ref-type="table-fn"}   6.2±2.1          0.670[b](#tfn6-cia-11-1675){ref-type="table-fn"}

   10 weeks                               5.9±4.9                                                                 5.8±3.9          

  Insulin-like growth factor-1 (ng/mL)                                                                                             

   Baseline                               92.7±37.8            0.585[b](#tfn6-cia-11-1675){ref-type="table-fn"}   102.2±47.5       0.898[b](#tfn6-cia-11-1675){ref-type="table-fn"}

   10 weeks                               103.9±65                                                                99.7±65.3        

  Total L-carnitine (μmol/L)                                                                                                       

   Baseline                               36.1±14.3            0.606[b](#tfn6-cia-11-1675){ref-type="table-fn"}   35.6±14.8        0.130[b](#tfn6-cia-11-1675){ref-type="table-fn"}

   10 weeks                               38.8±18.1                                                               37±20.6          

  Free L-carnitine (μmol/L)                                                                                                        

   Baseline                               32.4±12.4            0.845[b](#tfn6-cia-11-1675){ref-type="table-fn"}   26.9±11.6        0.516[b](#tfn6-cia-11-1675){ref-type="table-fn"}

   10 weeks                               33.9±5.1                                                                31.1±3.3         

  Acyl L-carnitine (μmol/L)                                                                                                        

   Baseline                               3.6±14.9             0.905[b](#tfn6-cia-11-1675){ref-type="table-fn"}   8.6±15.2         0.819[b](#tfn6-cia-11-1675){ref-type="table-fn"}

   10 weeks                               3.1±20.4                                                                7.6±17.8         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

*P*\<0.05,

*P*\<0.01,

using Friedman test,

using Wilcoxon test.

**Abbreviations:** PASE, Physical Activity Scale for Elderly; SD, standard deviation; NA, not applicable.

###### 

Self-reported side effect by subjects (presented as n \[%\])

  Side effect              L-carnitine group (%)   Placebo group (%)   *P*-value
  ------------------------ ----------------------- ------------------- ---------------------------------------------------
  General feeling                                                      
   Normal                  19 (73.1)               17 (70.8)           0.554
   Better                  7 (26.9)                7 (29.2)            
   Worse                   0 (0)                   0 (0)               
  Feeling more energetic                                               
   Yes                     11 (42.3)               4 (16.7)            0.047[\*](#tfn8-cia-11-1675){ref-type="table-fn"}
   No                      15 (57.7)               20 (83.3)           
  Nausea                                                               
   Yes                     0 (0)                   0 (0)               0.674
   No                      26 (100)                24 (100)            
  Vomiting                                                             
   Yes                     0 (0)                   0 (0)               0.603
   No                      26 (100)                24 (100)            
  Diarrhea                                                             
   Yes                     0 (0)                   0 (0)               0.456
   No                      26 (100)                24 (100)            
  Constipation                                                         
   Yes                     1 (3.8)                 0 (0)               0.476
   No                      25 (96.2)               24 (100)            
  Muscle pain                                                          
   Yes                     0 (0)                   1 (4.2)             0.334
   No                      26 (100)                23 (95.8)           
  Appetite                                                             
   Increased               2 (7.7)                 0 (0)               0.443
   Same                    23 (88.5)               20 (83.3)           
   Decrease                1 (3.8)                 4 (16.7)            
  Sleep                                                                
   More                    0 (0)                   1 (4.2)             0.443
   Same                    26 (100)                23 (95.8)           
   Less                    0 (0)                   0 (0)               

**Note:**

*P*\<0.05 using chi-square test.
